Press Release Archives | Page 21 of 23

Oncotarget News

Oncotarget | Tumor Hyaluronan as Novel Biomarker in Non-Small Cell Lung Cancer: A Retrospective Study

November 9, 2022

To the best of our knowledge, there have only been 2 other studies (both retrospective) investigating the prognostic potential of HA in NSCLC patients [5, 6].”BUFFALO, NY- November 9,... read more

Oncotarget

Oncotarget | Predictive Molecular Biomarkers for Determining Neoadjuvant Chemosensitivity in Muscle Invasive Bladder Cancer

November 8, 2022

To our knowledge, our study is the first to use combined differential mRNA and miRNA expression in MIBC to identify a NAC response signature.”BUFFALO, NY- November 8, 2022 – A... read more

Oncotarget

Oncotarget | Serine Protease Matriptase Inhibits Migration and Proliferation in Multiple Myeloma Cells

November 7, 2022

We demonstrate that matriptase overexpression in vitro was associated with reduced myeloma cell proliferation and that matriptase significantly inhibited myeloma cell migration.”BUFFALO, NY- November 7, 2022 – A new research... read more

Oncotarget

Oncotarget | Nectin-4 Widely Expressed in Head and Neck Squamous Cell Carcinoma

November 3, 2022

In this study, we aimed to determine the rate of Nectin-4 positivity in a contemporary cohort of HNSCC and to correlate these findings with clinico-pathological parameters.”BUFFALO, NY- November 3,... read more

Oncotarget

Oncotarget is Again on MEDLINE

October 27, 2022

BUFFALO, NY- October 27, 2022 – On September 15, 2022, Oncotarget was accepted again for indexing by MEDLINE. Oncotarget is now indexed by MEDLINE/PubMed and PubMed Central/PubMed.The United... read more

Oncotarget

Oncotarget | Therapeutic Efficacy of Humanized JAA-F11 Anti-Thomsen-Friedenreich Antibody Constructs H2aL2a and H3L3 in Human Breast and Lung Cancer Xenograft Models

October 25, 2022

The potential therapeutic efficacy of the humanized antibodies to TF-Ag-α, hJAA-F11-H2aL2a and hJAA-F11-H3L3, was assessed in human breast and lung cancer xenograft models.”BUFFALO, NY- October 25, 2022 – A new... read more

Oncotarget

Oncotarget | Platelet-derived Growth Factor (PDGF) Cross-Signaling Via Non-Corresponding Receptors Indicates Bypassed Signaling in Colorectal Cancer

October 20, 2022

The present study analyzed PDGFR and VEGFR expression in primary colon cancer tissues and CRC cell lines in order to better define their expression profiles. Furthermore, we analyzed putative PDGF... read more

Oncotarget

Oncotarget | Effectiveness of Radiotherapy for Local Control in T3N0 Rectal Cancer Managed With Total Mesorectal Excision: A Meta-analysis

October 13, 2022

To the best of our knowledge, this is the first study to date to perform a systematic review or meta-analysis regarding the benefit of radiotherapy specific to the T3N0 rectal... read more

Oncotarget

Oncotarget | In vitro Chemotherapy-associated Muscle Toxicity Attenuated With Nutritional Support, While Treatment Efficacy Retained

October 11, 2022

Our in vitro study demonstrates the importance of specialized nutritional support and combining multiple nutrients to reach maximum effect to attenuate chemotherapy-associated muscle toxicity of skeletal muscle in cancer patients.”... read more

Oncotarget

Oncotarget | Genomic Alterations Predictive of Poor Clinical Outcomes in Pan-cancer

October 4, 2022

PRESS RELEASE: A new research paper was published in Oncotarget's Volume 13 on September 28, 2022, entitled, “Genomic alterations predictive of poor clinical outcomes in pan-cancer.”BUFFALO, NY- October 4,... read more